Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Bolam, E. Pissadaki (2012)
Living on the edge with too many mouths to feed: Why dopamine neurons dieMovement Disorders, 27
A. Espay, J. Vizcarra, L. Marsili, A. Lang, D. Simon, A. Merola, K. Josephs, A. Fasano, F. Morgante, R. Savica, J. Greenamyre, F. Cambi, T. Yamasaki, C. Tanner, Z. Gan-Or, I. Litvan, I. Mata, C. Zabetian, P. Brundin, H. Fernandez, D. Standaert, M. Kauffman, M. Schwarzschild, S. Sardi, T. Sherer, George Perry, J. Leverenz (2019)
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.Neurology, 92 7
G. Paul, W. Meissner, S. Rein, D. Harnack, C. Winter, Kai Hosmann, R. Morgenstern, A. Kupsch (2004)
Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's diseaseExperimental Neurology, 185
H. Braak, K. Tredici, U. Rüb, R. Vos, Ernst Steur, E. Braak (2003)
Staging of brain pathology related to sporadic Parkinson’s diseaseNeurobiology of Aging, 24
H. Bergman, T. Wichmann, B. Karmon, M. DeLong (1994)
The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.Journal of neurophysiology, 72 2
J. Obeso, M. Stamelou, C. Goetz, W. Poewe, A. Lang, A. Lang, D. Weintraub, D. Burn, G. Halliday, G. Halliday, E. Bézard, E. Bézard, S. Przedborski, S. Lehéricy, D. Brooks, D. Brooks, J. Rothwell, M. Hallett, M. DeLong, C. Marras, C. Tanner, C. Tanner, G. Ross, J. Langston, C. Klein, V. Bonifati, J. Jankovic, A. Lozano, G. Deuschl, H. Bergman, E. Tolosa, M. Rodríguez‐Violante, S. Fahn, R. Postuma, D. Berg, K. Marek, D. Standaert, D. Surmeier, C. Olanow, J. Kordower, P. Calabresi, A. Schapira, A. Stoessl, A. Stoessl (2017)
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking PalsyMovement Disorders, 32
E. Sidransky, G. Lopez (2012)
The link between the GBA gene and parkinsonismThe Lancet Neurology, 11
Hugh Chan, H. Paur, A. Vernon, Virginia Zabarsky, K. Datla, M. Croucher, D. Dexter (2010)
Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's DiseaseParkinson's Disease, 2010
P. Chan, J. Langston, D. Monte (1993)
MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum.The Journal of pharmacology and experimental therapeutics, 267 3
T. Hashimoto, Christopher Elder, M. Okun, S. Patrick, J. Vitek (2003)
Stimulation of the Subthalamic Nucleus Changes the Firing Pattern of Pallidal NeuronsThe Journal of Neuroscience, 23
D. Centonze, P. Gubellini, S. Rossi, B. Picconi, A. Pisani, G. Bernardi, P. Calabresi, C. Baunez (2005)
Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonismNeuroscience, 133
R. Price, Delaney Fisher, J. Suk, J. Hanes, H. Ko, J. Kordower (2019)
Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier?Movement Disorders, 34
Aaron Bond, Binit Shah, D. Huss, R. Dallapiazza, Amy Warren, M. Harrison, S. Sperling, Xin-Qun Wang, R. Gwinn, Jennie Witt, Susie Ro, W. Elias (2017)
Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical TrialJAMA Neurology, 74
Gerhard Leinenga, C. Langton, Rebecca Nisbet, J. Götz (2016)
Ultrasound treatment of neurological diseases — current and emerging applicationsNature Reviews Neurology, 12
T. Mestre, A. Espay, C. Marras, M. Eckman, P. Pollak, A. Lang (2014)
Subthalamic nucleus‐deep brain stimulation for early motor complications in Parkinson's disease—the EARLYSTIM trial: Early is not always betterMovement Disorders, 29
A. Zuddas, G. Oberto, F. Vaglini, F. Fascetti, F. Fornai, G. Corsini (1992)
MK‐801 Prevents 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine‐Induced Parkinsonism in PrimatesJournal of Neurochemistry, 59
P. LeWitt, N. Lipsman, J. Kordower (2019)
Focused ultrasound opening of the blood–brain barrier for treatment of Parkinson's diseaseMovement Disorders, 34
N. Hosseinkhah, D. Goertz, K. Hynynen (2015)
Microbubbles and Blood–Brain Barrier Opening: A Numerical Study on Acoustic Emissions and Wall Stress PredictionsIEEE Transactions on Biomedical Engineering, 62
François Windels, Nicolas Bruet, A. Poupard, N. Urbain, G. Chouvet, C. Feuerstein, M. Savasta (2000)
Effects of high frequency stimulation of subthalamic nucleus on extracellular glutamate and GABA in substantia nigra and globus pallidus in the normal ratEuropean Journal of Neuroscience, 12
K. Tredici, H. Braak (2016)
Review: Sporadic Parkinson's disease: development and distribution of α‐synuclein pathologyNeuropathology and Applied Neurobiology, 42
T. Uchihara, B. Giasson (2015)
Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studiesActa Neuropathologica, 131
M. Merino, Marisa Vizuete, J. Cano, A. Machado (1999)
The Non‐NMDA Glutamate Receptor Antagonists 6‐Cyano‐7‐Nitroquinoxaline‐2,3‐dione and 2,3‐Dihydroxy‐6‐Nitro‐7‐Sulfamoylbenzo(f)quinoxaline, but Not NMDA Antagonists, Block the Intrastriatal Neurotoxic Effect of MPP+Journal of Neurochemistry, 73
Ahmad Elkouzi, V. Vedam-Mai, R. Eisinger, M. Okun (2019)
Emerging therapies in Parkinson disease — repurposed drugs and new approachesNature Reviews Neurology, 15
M. O'Neill, T. Murray, K. Whalley, M. Ward, C. Hicks, S. Woodhouse, D. Osborne, P. Skolnick (2004)
Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.European journal of pharmacology, 486 2
D. Fischer, F. Manfredsson, C. Kemp, A. Cole-Strauss, J. Lipton, Megan Duffy, N. Polinski, K. Steece-Collier, T. Collier, S. Gombash, Daniel Buhlinger, C. Sortwell (2017)
Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein OverexpressionScientific Reports, 7
N. Lipsman, Y. Meng, A. Bethune, Yuexi Huang, B. Lam, M. Masellis, N. Herrmann, C. Heyn, I. Aubert, A. Boutet, Gwenn Smith, K. Hynynen, S. Black (2018)
Blood–brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasoundNature Communications, 9
(2018)
State-of-the-art of microbubbleassisted blood-brain barrier disruption
C. Olanow, J. Obeso (2012)
The significance of defining preclinical or prodromal Parkinson's diseaseMovement Disorders, 27
A. Vernon, S. Palmer, K. Datla, V. Zbarsky, M. Croucher, D. Dexter (2005)
Neuroprotective effects of metabotropic glutamate receptor ligands in a 6‐hydroxydopamine rodent model of Parkinson's diseaseEuropean Journal of Neuroscience, 22
K. Dorovini‐Zis, P. Bowman, A. Betz, G. Goldstein (1984)
Hyperosmotic arabinose solutions open the tight junctions between brain capillary endothelial cells in tissue cultureBrain Research, 302
R. Albin, J. Aldridge, A. Young, S. Gilman (1989)
Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivityBrain Research, 491
J. Jordão, E. Thévenot, K. Markham-Coultes, Tiffany Scarcelli, Ying-Qi Weng, Kristiana Xhima, Meaghan O'Reilly, Yuexi Huang, J. McLaurin, K. Hynynen, I. Aubert (2013)
Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasoundExperimental Neurology, 248
G. Foffani, J. Obeso (2018)
A Cortical Pathogenic Theory of Parkinson’s DiseaseNeuron, 99
Vanesa Sanchez-guajardo, Noemie Tentillier, M. Romero-Ramos (2015)
The relation between α-synuclein and microglia in Parkinson’s disease: Recent developmentsNeuroscience, 302
Gerhard Leinenga, J. Götz (2015)
Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse modelScience Translational Medicine, 7
Behavior Disorder
B. Wallace, K. Ashkan, Claire Heise, K. Foote, N. Torres, J. Mitrofanis, A. Benabid (2007)
Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys.Brain : a journal of neurology, 130 Pt 8
G. Ambrosi, S. Cerri, F. Blandini (2013)
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s diseaseJournal of Neural Transmission, 121
F. Sato, M. Parent, M. Lévesque, A. Parent (2000)
Axonal branching pattern of neurons of the subthalamic nucleus in primatesJournal of Comparative Neurology, 424
G. Carvalho, G. Nikkhah (2001)
Subthalamic Nucleus Lesions Are Neuroprotective against Terminal 6-OHDA-Induced Striatal Lesions and Restore Postural Balancing ReactionsExperimental Neurology, 171
(2017)
Effects of alpha-synuclein on axonal transport
N. Nakao, E. Nakai, K. Nakai, T. Itakura (1999)
Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3‐nitropropionic acidAnnals of Neurology, 45
S. Schreglmann, J. Krauss, J. Chang, K. Bhatia, G. Kägi (2018)
Functional lesional neurosurgery for tremor: a systematic review and meta-analysisJournal of Neurology, Neurosurgery, and Psychiatry, 89
K. Cordeiro, J. Cordeiro, L. Furlanetti, Salazar Garcia, S. Tenório, C. Winkler, M. Döbrössy, G. Nikkhah (2014)
Subthalamic nucleus lesion improves cell survival and functional recovery following dopaminergic cell transplantation in parkinsonian ratsEuropean Journal of Neuroscience, 39
F. Marquet, Y. Tung, T. Teichert, V. Ferrera, E. Konofagou (2011)
Noninvasive, Transient and Selective Blood-Brain Barrier Opening in Non-Human Primates In VivoPLoS ONE, 6
K. Song, B. Harvey, M. Borden (2018)
State-of-the-art of microbubble-assisted blood-brain barrier disruptionTheranostics, 8
L. Turski, K. Bressler, K. Rettig, P. Löschmann, H. Wachtel (1991)
Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonistsNature, 349
R. Niranjan (2013)
The Role of Inflammatory and Oxidative Stress Mechanisms in the Pathogenesis of Parkinson’s Disease: Focus on AstrocytesMolecular Neurobiology, 49
C. Hammond, J. Deniau, A. Rizk, J. Féger (1978)
Electrophysiological demonstration of an excitatory subthalamonigral pathway in the ratBrain Research, 151
M. Kinoshita, N. McDannold, F. Jolesz, K. Hynynen (2006)
Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption.Proceedings of the National Academy of Sciences of the United States of America, 103 31
A. Wright, J. Atherton, L. Norrie, G. Arbuthnott (2004)
Death of dopaminergic neurones in the rat substantia nigra can be induced by damage to globus pallidusEuropean Journal of Neuroscience, 20
D. Fischer, C. Sortwell (2018)
BDNF provides many routes toward STN DBS‐mediated disease modificationMovement Disorders, 34
Lin Chen, Zong-hui Liu, Z. Tian, Yaqi Wang, Shiyue Li (2001)
Prevention of Neurotoxin Damage of 6-OHDA to Dopaminergic Nigral Neuron by Subthalamic Nucleus LesionsStereotactic and Functional Neurosurgery, 75
(2014)
Extracellular alpha--synuclein-a novel and crucial factor in Lewybody diseases
R. Walker, Georgia Davies, R. Koch, A. Haack, C. Moore, C. Meshul (2010)
Effects of zona incerta lesions on striatal neurochemistry and behavioral asymmetry in 6‐hydroxydopamine‐lesioned ratsJournal of Neuroscience Research, 88
A. Parent, L. Hazrati (1995)
Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidium in basal ganglia circuitryBrain Research Reviews, 20
N. McDannold, N. Vykhodtseva, S. Raymond, F. Jolesz, K. Hynynen (2005)
MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits.Ultrasound in medicine & biology, 31 11
F. Blandini (2001)
The role of the subthalamic nucleus in the pathophysiology of Parkinson's disease.Functional neurology, 16 4 Suppl
W. Elias, N. Lipsman, W. Ondo, P. Ghanouni, Y. Kim, W. Lee, M. Schwartz, K. Hynynen, A. Lozano, Binit Shah, D. Huss, R. Dallapiazza, R. Gwinn, Jennifer Witt, Susie Ro, H. Eisenberg, P. Fishman, D. Gandhi, C. Halpern, R. Chuang, K. Pauly, T. Tierney, M. Hayes, G. Cosgrove, Toshio Yamaguchi, K. Abe, T. Taira, J. Chang (2016)
A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor.The New England journal of medicine, 375 8
M. Karakatsani, J. Blesa, E. Konofagou (2019)
Blood–brain barrier opening with focused ultrasound in experimental models of Parkinson's diseaseMovement Disorders, 34
C. Hammond, H. Bergman, P. Brown (2007)
Pathological synchronization in Parkinson's disease: networks, models and treatmentsTrends in Neurosciences, 30
Na Jung, C. Park, Minsoo Kim, P. Lee, Y. Sohn, J. Chang (2019)
The efficacy and limits of magnetic resonance-guided focused ultrasound pallidotomy for Parkinson's disease: a Phase I clinical trial.Journal of neurosurgery
Jinmu Deng, Qin Huang, Feng Wang, Yingjiang Liu, Zhibiao Wang, Zhi-gang Wang, Qingtao Zhang, B. Lei, Yuan Cheng (2011)
The Role of Caveolin-1 in Blood–Brain Barrier Disruption Induced by Focused Ultrasound Combined with MicrobubblesJournal of Molecular Neuroscience, 46
K. Hynynen, N. McDannold, N. Sheikov, F. Jolesz, N. Vykhodtseva (2005)
Local and reversible blood–brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonicationsNeuroImage, 24
A. Wright, G. Arbuthnott (2007)
The influence of the subthalamic nucleus upon the damage to the dopamine system following lesions of globus pallidus in ratsEuropean Journal of Neuroscience, 26
N. Maurice, A. Thierry, J. Glowinski, J. Deniau (2003)
Spontaneous and Evoked Activity of Substantia Nigra Pars Reticulata Neurons during High-Frequency Stimulation of the Subthalamic NucleusThe Journal of Neuroscience, 23
N. McDannold, C. Arvanitis, N. Vykhodtseva, M. Livingstone (2012)
Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques.Cancer research, 72 14
A. Mesiwala, Lindi Farrell, H. Wenzel, D. Silbergeld, L. Crum, H. Winn, P. Mourad (2002)
High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo.Ultrasound in medicine & biology, 28 3
D. Joel, I. Weiner
Full-length Review
J. Guridi, J. Obeso (2001)
The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma.Brain : a journal of neurology, 124 Pt 1
(1996)
Subthalamotomy in parkinsonian monkeys
K. Hynynen, F. Jolesz (1998)
Demonstration of potential noninvasive ultrasound brain therapy through an intact skull.Ultrasound in medicine & biology, 24 2
Thomas Barber, M. Lawton, M. Rolinski, Samuel Evetts, F. Baig, C. Ruffmann, Aimie Gornall, J. Klein, Christine Lo, G. Dennis, O. Bandmann, T. Quinnell, Z. Zaiwalla, Y. Ben-Shlomo, M. Hu (2017)
Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior DisorderSleep, 40
G. Deuschl, C. Schade-Brittinger, P. Krack, J. Volkmann, H. Schäfer, K. Bötzel, C. Daniels, A. Deutschländer, U. Dillmann, W. Eisner, D. Gruber, W. Hamel, J. Herzog, R. Hilker, S. Klebe, M. Kloss, J. Koy, M. Krause, A. Kupsch, D. Lorenz, S. Lorenzl, H. Mehdorn, J. Moringlane, W. Oertel, M. Pinsker, H. Reichmann, A. Reuss, G. Schneider, A. Schnitzler, U. Steude, V. Sturm, L. Timmermann, V. Tronnier, T. Trottenberg, L. Wojtecki, E. Wolf, W. Poewe, J. Voges (2006)
A randomized trial of deep-brain stimulation for Parkinson's disease.The New England journal of medicine, 355 9
E. Bézard, T. Boraud, B. Bioulac, C. Gross (1999)
Involvement of the subthalamic nucleus in glutamatergic compensatory mechanismsEuropean Journal of Neuroscience, 11
E. Brouillet, M. Beal (1993)
NMDA antagonists partially protect against MPTP induced neurotoxicity in miceNeuroReport, 4
Tony Wang (2015)
Neurological applications of transcranial high intensity focused ultrasoundInternational Journal of Hyperthermia, 31
Tereza Alecou, M. Giannakou, C. Damianou (2017)
Amyloid β Plaque Reduction With Antibodies Crossing the Blood‐Brain Barrier, Which Was Opened in 3 Sessions of Focused Ultrasound in a Rabbit ModelJournal of Ultrasound in Medicine, 36
SynapticMechanisms ofNeuronal Vulnerability in ParkinsonDisease
C. Winter, Kai Hosmann, D. Harnack, W. Meissner, G. Paul, R. Morgenstern, A. Kupsch (2006)
Subthalamic nucleus lesioning inhibits expression and phosphorylation of c‐Jun in nigral neurons in the rat's 6‐OHDA model of Parkinson's diseaseSynapse, 60
Victoria Shaw, K. Keay, K. Ashkan, A. Benabid, J. Mitrofanis (2010)
Dopaminergic cells in the periaqueductal grey matter of MPTP-treated monkeys and mice; patterns of survival and effect of deep brain stimulation and lesion of the subthalamic nucleus.Parkinsonism & related disorders, 16 5
T. Murray, K. Whalley, C. Robinson, M. Ward, C. Hicks, D. Lodge, Jim Vandergriff, P. Baumbarger, E. Siuda, M. Gates, A. Ogden, P. Skolnick, D. Zimmerman, E. Nisenbaum, D. Bleakman, M. O'Neill (2003)
LY503430, a Novel α-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson's DiseaseJournal of Pharmacology and Experimental Therapeutics, 306
P. LeWitt, A. Rezai, M. Leehey, S. Ojemann, A. Feigin, S. Tatter (2011)
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trialThe Lancet Neurology, 10
Wolfgang Wiedemair, Ž. Tuković, H. Jasak, D. Poulikakos, V. Kurtcuoglu (2017)
The breakup of intravascular microbubbles and its impact on the endotheliumBiomechanics and Modeling in Mechanobiology, 16
He‐Jin Lee, Eun-Jin Bae, Seung-Jae Lee (2014)
Extracellular α-synuclein—a novel and crucial factor in Lewy body diseasesNature Reviews Neurology, 10
R. Cilia, S. Tunesi, G. Marotta, E. Cereda, C. Siri, S. Tesei, A. Zecchinelli, M. Canesi, C. Mariani, N. Meucci, G. Sacilotto, M. Zini, M. Barichella, C. Magnani, S. Duga, R. Asselta, G. Soldà, A. Seresini, M. Seia, G. Pezzoli, S. Goldwurm (2016)
Survival and dementia in GBA‐associated Parkinson's disease: The mutation mattersAnnals of Neurology, 80
W. Banks (2016)
From blood–brain barrier to blood–brain interface: new opportunities for CNS drug deliveryNature Reviews Drug Discovery, 15
J. Cedarbaum (2018)
Elephants, Parkinson's Disease, and Proof‐of‐Concept Clinical TrialsMovement Disorders, 33
Nicolas Dzamko, Nicolas Dzamko, C. Geczy, G. Halliday, G. Halliday (2015)
Inflammation is genetically implicated in Parkinson’s diseaseNeuroscience, 302
J. Blesa, Inés Trigo-Damas, M. Dileone, N. Rey, L. Hernandez, J. Obeso (2017)
Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modificationExperimental Neurology, 298
T. Murray, K. Whalley, C. Robinson, M. Ward, C. Hicks, D. Lodge, Jim Vandergriff, P. Baumbarger, E. Siuda, M. Gates, A. Ogden, P. Skolnick, D. Zimmerman, E. Nisenbaum, D. Bleakman, M. O'Neill (2003)
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.The Journal of pharmacology and experimental therapeutics, 306 2
M. Betts, M. O'Neill, S. Duty (2012)
Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6‐hydroxydopamine rat model of Parkinson's diseaseBritish Journal of Pharmacology, 166
(2003)
Parkinson’s disease: mechanisms and models. Neuron 2003;39(6):889-909
Y. Meng, S. Suppiah, Karim Mithani, Benjamin Solomon, M. Schwartz, N. Lipsman (2017)
Current and emerging brain applications of MR-guided focused ultrasoundJournal of Therapeutic Ultrasound, 5
G. Deuschl, Y. Agid (2013)
Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefitsThe Lancet Neurology, 12
A. Oswal, M. Beudel, L. Zrinzo, P. Limousin, M. Hariz, T. Foltynie, V. Litvak, P. Brown (2016)
Deep brain stimulation modulates synchrony within spatially and spectrally distinct resting state networks in Parkinson’s diseaseBrain, 139
M. Karakatsani, Shutao Wang, G. Samiotaki, Tara Kugelman, Oluyemi Olumolade, C. Acosta, T. Sun, Yang Han, H. Kamimura, V. Jackson-Lewis, S. Przedborski, E. Konofagou (2019)
Amelioration of the nigrostriatal pathway facilitated by ultrasound-mediated neurotrophic delivery in early Parkinson's disease.Journal of controlled release : official journal of the Controlled Release Society, 303
C. Pacelli, N. Giguère, Marie-Josée Bourque, M. Lévesque, R. Slack, L. Trudeau (2015)
Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine NeuronsCurrent Biology, 25
D. Harnack, W. Meissner, Julia Jira, C. Winter, R. Morgenstern, A. Kupsch (2008)
Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive ParkinsonismExperimental Neurology, 210
S. Maesawa, Y. Kaneoke, Y. Kajita, N. Usui, Nobuaki Misawa, A. Nakayama, J. Yoshida (2004)
Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons.Journal of neurosurgery, 100 4
Rebecca Nisbet, A. Jeugd, Gerhard Leinenga, H. Evans, Phillip Janowicz, J. Götz (2017)
Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse modelBrain, 140
M. Armentero, R. Fancellu, G. Nappi, P. Bramanti, F. Blandini (2006)
Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's diseaseNeurobiology of Disease, 22
Y. Smith, A. Parent (1988)
Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivityBrain Research, 453
Zsofia Kovacs, Saejeong Kim, Neekita Jikaria, Farhan Qureshi, Blerta Milo, B. Lewis, Michele Bresler, S. Burks, J. Frank (2016)
Disrupting the blood–brain barrier by focused ultrasound induces sterile inflammationProceedings of the National Academy of Sciences, 114
(2019)
SynapticMechanisms ofNeuronal Vulnerability in ParkinsonDisease.MovDisord 2019;34
M. Hacker, M. DeLong, M. Turchan, L. Heusinkveld, J. Ostrem, A. Molinari, Amanda Currie, P. Konrad, T. Davis, Fenna Phibbs, P. Hedera, K. Cannard, Lea Drye, A. Sternberg, David Shade, J. Tonascia, D. Charles (2018)
Effects of deep brain stimulation on rest tremor progression in early stage Parkinson diseaseNeurology, 91
L. Volpicelli-Daley (2017)
Effects of α-synuclein on axonal transportNeurobiology of Disease, 105
(2019)
Blood Brain Barrier Opening with Low Frequency Focused Ultrasound in Experimental Models of Parkinson’s Disease
W. Elias, D. Huss, T. Voss, Johanna Loomba, Mohamad Khaled, E. Zadicario, R. Frysinger, S. Sperling, S. Wylie, S. Monteith, J.T. Druzgal, Binit Shah, M. Harrison, M. Wintermark (2013)
A pilot study of focused ultrasound thalamotomy for essential tremor.The New England journal of medicine, 369 7
M. Nguyen, Y. Wong, Daniel Ysselstein, A. Severino, D. Krainc (2019)
Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson’s DiseaseTrends in Neurosciences, 42
G. Masilamoni, J. Bogenpohl, D. Alagille, K. Delevich, G. Tamagnan, J. Votaw, T. Wichmann, Y. Smith (2011)
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.Brain : a journal of neurology, 134 Pt 7
K. Lange, P. Löschmann, E. Sofić, M. Burg, R. Horowski, K. Kalveram, H. Wachtel, P. Riederer (1993)
The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primatesNaunyn-Schmiedeberg's Archives of Pharmacology, 348
Anna Migdalska‐Richards, W. Ko, Qin Li, E. Bézard, A. Schapira (2017)
Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primateSynapse (New York, N.y.), 71
Anne Spieles-Engemann, M. Behbehani, T. Collier, S. Wohlgenant, K. Steece-Collier, K. Paumier, B. Daley, S. Gombash, L. Madhavan, G. Mandybur, J. Lipton, B. Terpstra, C. Sortwell (2010)
Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron lossNeurobiology of Disease, 39
M. Brightman, M. Hori, S. Rapoport, T. Reese, E. Westergaard (1973)
Osmotic opening of tight junctions in cerebral endotheliumJournal of Comparative Neurology, 152
Kristiana Xhima, Fadl Nabbouh, K. Hynynen, I. Aubert, A. Tandon (2018)
Noninvasive delivery of an α‐synuclein gene silencing vector with magnetic resonance–guided focused ultrasoundMovement Disorders, 33
R. Walker, R. Koch, J. Sweeney, C. Moore, C. Meshul (2009)
Effects of subthalamic nucleus lesions and stimulation upon glutamate levels in the dopamine-depleted rat striatumNeuroReport, 20
Matthew Downs, A. Buch, M. Karakatsani, E. Konofagou, V. Ferrera (2015)
Blood-Brain Barrier Opening in Behaving Non-Human Primates via Focused Ultrasound with Systemically Administered MicrobubblesScientific Reports, 5
Zhen Zhao, Amy Nelson, C. Betsholtz, B. Zlokovic (2015)
Establishment and Dysfunction of the Blood-Brain BarrierCell, 163
G. Samiotaki, C. Acosta, Shutao Wang, E. Konofagou (2015)
Enhanced Delivery and Bioactivity of the Neurturin Neurotrophic Factor through Focused Ultrasound—Mediated Blood—Brain Barrier Opening in vivoJournal of Cerebral Blood Flow & Metabolism, 35
M. Luquin, L. Saldise, J. Guillén, S. Belzunegui, W. Sebastián, A. Izal, Pablo Garrido, Marianne Vázquez (2006)
Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease?Experimental Neurology, 201
R. Albin, J. Greenamyre (1992)
Alternative excitotoxic hypothesesNeurology, 42
MD Rodriguez, MD Obeso, MD Olanow, Str GPe, GPi Thalamus (1998)
Subthalamic nucleus‐mediated excitotoxicity in parkinson's disease: A target for neuroprotectionAnnals of Neurology, 44
D. Surmeier, J. Obeso, J. Obeso, G. Halliday, G. Halliday (2017)
Selective neuronal vulnerability in Parkinson diseaseNature Reviews Neuroscience, 18
T. Collier, N. Kanaan, J. Kordower (2011)
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primatesNature Reviews Neuroscience, 12
Gian Pal, B. Ouyang, L. Verhagen, G. Serrano, H. Shill, C. Adler, T. Beach, J. Kordower (2018)
Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's diseaseMovement Disorders, 33
Feng-Yi Yang, Sheng-Fang Huang, I. Cheng (2016)
Behavioral alterations following blood-brain barrier disruption stimulated by focused ultrasoundOncotarget, 7
G. Foffani, G. Foffani, A. Pesenti, F. Tamma, A. Bianchi, M. Pellegrini, M. Locatelli, K. Moxon, R. Villani (2004)
Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's diseaseExperimental Neurology, 189
S. Rapoport, M. Hori, I. Klatzo (1972)
Testing of a hypothesis for osmotic opening of the blood-brain barrier.The American journal of physiology, 223 2
(2019)
Development of an aggregateselective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models
J. Jordão, C. Ayala-Grosso, Kelly Markham, Yuexi Huang, Rajiv Chopra, J. McLaurin, K. Hynynen, I. Aubert (2010)
Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid-β Plaque Load in the TgCRND8 Mouse Model of Alzheimer's DiseasePLoS ONE, 5
Hsiao-Chun Cheng, C. Ulane, R. Burke (2010)
Clinical progression in Parkinson disease and the neurobiology of axonsAnnals of Neurology, 67
M. Hsieh, Shih-Chun Ho, K. Yeh, C. Pawlak, Hung-Ming Chang, Y. Ho, T. Lai, Fu-Ying Wu (2012)
Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat modelPharmacology Biochemistry and Behavior, 102
R. Yılmaz, F. Hopfner, T. Eimeren, D. Berg (2019)
Biomarkers of Parkinson’s disease: 20 years laterJournal of Neural Transmission
J. Guridi, M. Herrero, M. Luquin, J. Guillén, M. Ruberg, J. Laguna, M. Vila, F. Javoy‐Agid, Y. Agid, E. Hirsch, J. Obeso (1996)
Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis.Brain : a journal of neurology, 119 ( Pt 5)
W. Schuepbach, J. Rau, K. Knudsen, J. Volkmann, P. Krack, L. Timmermann, T. Hälbig, Helke Hesekamp, S. Navarro, N. Meier, D. Falk, M. Mehdorn, S. Paschen, M. Maarouf, M. Barbe, G. Fink, A. Kupsch, D. Gruber, G. Schneider, E. Seigneuret, A. Kistner, P. Chaynes, F. Ory-Magne, C. Courbon, J. Vesper, A. Schnitzler, L. Wojtecki, J. Houeto, B. Bataille, D. Maltête, P. Damier, S. Raoul, F. Sixel-Doering, D. Hellwig, A. Gharabaghi, R. Krüger, M. Pinsker, F. Amtage, Jean-Marie Régis, T. Witjas, S. Thobois, P. Mertens, M. Kloss, A. Hartmann, W. Oertel, B. Post, H. Speelman, Y. Agid, C. Schade-Brittinger, G. Deuschl (2013)
Neurostimulation for Parkinson's disease with early motor complications.The New England journal of medicine, 368 7
M. Fuzzati‐Armentero, S. Cerri, G. Levandis, G. Ambrosi, Elena Montepeloso, Gianfilippo Antoninetti, F. Blandini, Younis Baqi, C. Müller, R. Volpini, Giulia Costa, N. Simola, A. Pinna (2015)
Dual target strategy: combining distinct non‐dopaminergic treatments reduces neuronal cell loss and synergistically modulates l‐DOPA‐induced rotational behavior in a rodent model of Parkinson's diseaseJournal of Neurochemistry, 134
Dymka Coudé, A. Parent, M. Parent (2018)
Single-axon tracing of the corticosubthalamic hyperdirect pathway in primatesBrain Structure and Function, 223
B. Högl, A. Stefani, A. Videnovic (2018)
Idiopathic REM sleep behaviour disorder and neurodegeneration — an updateNature Reviews Neurology, 14
Alice Filippini, M. Gennarelli, Isabella Russo (2019)
α-Synuclein and Glia in Parkinson’s Disease: A Beneficial or a Detrimental Duet for the Endo-Lysosomal System?Cellular and Molecular Neurobiology, 39
Benjamin Deverman, B. Ravina, K. Bankiewicz, S. Paul, D. Sah (2018)
Gene therapy for neurological disorders: progress and prospectsNature Reviews Drug Discovery, 17
Nasser Mohammed, D. Patra, A. Nanda (2018)
Erratum. A meta-analysis of outcomes and complications of magnetic resonance-guided focused ultrasound in the treatment of essential tremor.Neurosurgical focus, 45 1
R. Postuma, D. Berg (2019)
Prodromal Parkinson's Disease: The Decade Past, the Decade to ComeMovement Disorders, 34
Y. Higuchi, S. Matsuda, T. Serizawa (2017)
Gamma knife radiosurgery in movement disorders: Indications and limitationsMovement Disorders, 32
A. Sharott, Federica Vinciati, KouichiC Nakamura, P. Magill (2017)
A Population of Indirect Pathway Striatal Projection Neurons Is Selectively Entrained to Parkinsonian Beta OscillationsThe Journal of Neuroscience, 37
B. Piallat, A. Benazzouz, A. Benabid (1996)
Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical StudiesEuropean Journal of Neuroscience, 8
B. Meldrum, J. Garthwaite (1990)
Excitatory amino acid neurotoxicity and neurodegenerative disease.Trends in pharmacological sciences, 11 9
T. Murray, M. Messenger, M. Ward, S. Woodhouse, D. Osborne, S. Duty, M. O'Neill (2002)
Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's diseasePharmacology Biochemistry and Behavior, 73
V. Muddapu, A. Mandali, S. Chakravarthy, Srikanth Ramaswamy (2018)
A Computational Model of Loss of Dopaminergic Cells in Parkinson's Disease Due to Glutamate-Induced ExcitotoxicityFrontiers in Neural Circuits, 13
A. Zuddas, F. Vaglini, F. Fornai, F. Fascetti, A. Saginario, G. Corsini (1992)
Pharmacologic Modulation of MPTP Toxicity: MK 801 in Prevention of Dopaminergic Cell Death in Monkeys and MiceAnnals of the New York Academy of Sciences, 648
A. Alonso (2015)
Ultrasound-induced blood-brain barrier opening for drug delivery.Frontiers of neurology and neuroscience, 36
Houeto Jean-Luc (2022)
[Parkinson's disease].La Revue du praticien, 55 10
P. Brites, P. Mooyer, L. Mrabet, H. Waterham, Ronald Wanders (2008)
Plasmalogens participate in very-long-chain fatty acid-induced pathology.Brain : a journal of neurology, 132 Pt 2
T. Musacchio, Maike Rebenstorff, F. Fluri, J. Brotchie, J. Volkmann, J. Koprich, C. Ip (2017)
Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α‐synuclein Parkinson's disease rat modelAnnals of Neurology, 81
Andreas Weihofen, Yuting Liu, Joseph Arndt, C. Huy, C. Quan, Benjamin Smith, Jean-Luc Baeriswyl, Nicole Cavegn, Luzia Senn, Lihe Su, Galina Marsh, Pavan Auluck, F. Montrasio, Roger Nitsch, Warren Hirst, Jesse Cedarbaum, R. Pepinsky, J. Grimm, P. Weinreb (2019)
Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease modelsNeurobiology of Disease, 124
J. Guridi, R. Rodríguez-Rojas, M. Carmona-Abellán, O. Parras, Victoria Becerra, J. Lanciego (2018)
History and future challenges of the subthalamic nucleus as surgical target: Review articleMovement Disorders, 33
J. Kordower, R. Burke (2018)
Disease Modification for Parkinson's Disease: Axonal Regeneration and Trophic FactorsMovement Disorders, 33
Charissa Poon, D. McMahon, K. Hynynen (2017)
Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasoundNeuropharmacology, 120
R. Martínez-Fernández, R. Rodríguez-Rojas, M. Álamo, Frida Hernández-Fernández, J. Pineda-Pardo, M. Dileone, F. Alonso-Frech, G. Foffani, I. Obeso, C. Gasca-Salas, Esther Luis-Pastor, L. Vela, J. Obeso (2018)
Focused ultrasound subthalamotomy in patients with asymmetric Parkinson's disease: a pilot studyThe Lancet Neurology, 17
(2005)
Stanley Fahn Lecture
A. Ferrigno, M. Vairetti, G. Ambrosi, V. Rizzo, P. Richelmi, F. Blandini, M. Fuzzati‐Armentero (2015)
Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6‐OHDA lesioned Parkinsonian ratsClinical and Experimental Pharmacology and Physiology, 42
Y. Temel, V. Visser-Vandewalle, S. Kaplan, R. Kozan, M. Daemen, A. Blokland, C. Schmitz, H. Steinbusch (2006)
Protection of nigral cell death by bilateral subthalamic nucleus stimulationBrain Research, 1120
(2019)
BDNF provides many routes toward STN DBS-mediated diseasemodification.MovDisord 2019;34(1):22-34
Y. Wong, Kelvin Luk, K. Purtell, Samuel Burke, A. Stoessl, L. Trudeau, Zhenyu Yue, D. Krainc, W. Oertel, J. Obeso, L. Volpicelli-Daley (2019)
Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?Movement Disorders, 34
Pj Austin, M. Betts, M. Broadstock, M. O'Neill, Sn Mitchell, S. Duty (2010)
Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's diseaseBritish Journal of Pharmacology, 160
W. Dauer, S. Przedborski (2003)
Parkinson's Disease Mechanisms and ModelsNeuron, 39
P. Fishman, W. Elias, P. Ghanouni, R. Gwinn, N. Lipsman, M. Schwartz, Jin Chang, T. Taira, V. Krishna, A. Rezai, Kazumichi Yamada, K. Igase, Rees Cosgrove, H. Kashima, M. Kaplitt, T. Tierney, H. Eisenberg (2018)
Neurological adverse event profile of magnetic resonance imaging–guided focused ultrasound thalamotomy for essential tremorMovement Disorders, 33
P. Krack, R. Martínez-Fernández, M. Álamo, J. Obeso (2017)
Current applications and limitations of surgical treatments for movement disordersMovement Disorders, 32
P. LeWitt (2015)
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamicsMovement Disorders, 30
Greene Jg, Greenamyre Jt (1996)
Bioenergetics and glutamate excitotoxicity.Progress in Neurobiology, 48
R. Rodríguez-Rojas, M. Carballo-Barreda, L. Alvarez, J. Guridi, N. Pavón, I. García-Maeso, R. Macias, M. Rodriguez-Oroz, J. Obeso (2017)
Subthalamotomy for Parkinson’s disease: clinical outcome and topography of lesionsJournal of Neurology, Neurosurgery, and Psychiatry, 89
Po-Chun Chu, Hao-Li Liu, Hsin-Yi Lai, Chung-Yin Lin, H. Tsai, Y. Pei (2015)
Neuromodulation accompanying focused ultrasound-induced blood-brain barrier openingScientific Reports, 5
A. Lang, A. Espay (2018)
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future ConsiderationsMovement Disorders, 33
Feng-Yi Yang, Wen-Yuan Chang, Jyh-Cheng Chen, Lin-Chien Lee, Yi-Shun Hung (2014)
Quantitative assessment of cerebral glucose metabolic rates after blood–brain barrier disruption induced by focused ultrasound using FDG-MicroPETNeuroImage, 90
N. Abbott, A. Patabendige, D. Dolman, Siti Yusof, D. Begley (2010)
Structure and function of the blood–brain barrierNeurobiology of Disease, 37
James Choi, M. Pernot, S. Small, E. Konofagou (2007)
Noninvasive, transcranial and localized opening of the blood-brain barrier using focused ultrasound in mice.Ultrasound in medicine & biology, 33 1
S. Sardi, Catherine Viel, J. Clarke, Christopher Treleaven, A. Richards, Hyejung Park, Maureen Olszewski, J. Dodge, J. Marshall, Elina Makino, B. Wang, R. Sidman, Seng Cheng, L. Shihabuddin (2017)
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy modelsProceedings of the National Academy of Sciences, 114
H. Braak, J. Bohl, C. Müller, U. Rüb, R. Vos, K. Tredici (2006)
Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsideredMovement Disorders, 21
Z. Gan-Or, I. Amshalom, L. Kilarski, A. Bar‐Shira, M. Gana‐Weisz, A. Mirelman, K. Marder, S. Bressman, Nir Giladi, A. Orr-Urtreger (2015)
Differential effects of severe vs mild GBA mutations on Parkinson diseaseNeurology, 84
Marc-André Bellavance, Marie Blanchette, D. Fortin (2008)
Recent Advances in Blood–Brain Barrier Disruption as a CNS Delivery StrategyThe AAPS Journal, 10
A major unmet need in Parkinson's disease (PD) is to slow the inexorable progression of neurodegeneration. Clinical trials that evaluated promising pharmacological strategies have repeatedly failed. Nonetheless, the advent of focused ultrasound provides new opportunities toward the goal of developing a safe and effective disease‐modifying therapy for PD. Here we discuss the rationale, possible avenues, and challenges along this path, exploiting the potential of focused ultrasound for (1) performing focal thermal lesions to restore the basic basal ganglia abnormalities associated with dopamine depletion, and (2) transiently opening the blood–brain barrier for targeted delivery of therapeutic agents. First, the classic idea of excitotoxicity mediated by hyperactivity of the subthalamic nucleus suggests that focused ultrasound subthalamotomy may offer a clinically viable disease‐modifying therapy in very‐early PD. Second, the concept of retrograde nigrostriatal neurodegeneration, supported by our recent cortical pathogenic theory of PD, points toward the putamen as a principal site for focused ultrasound blood–brain barrier opening and targeted drug delivery. In principle, both therapeutic strategies—subthalamotomy and putaminal blood–brain barrier opening—could eventually be applied in the same patient. Clinical application is still a long road ahead; nevertheless, focused ultrasound may open a twofold path toward disease modification in PD. © 2019 International Parkinson and Movement Disorder Society
Movement Disorders – Wiley
Published: Sep 1, 2019
Keywords: ; ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.